title: [Risk of affective disorder in multiple sclerosis].
abstract: An increased risk for depression has been found in multiple sclerosis (MS). The purpose of the present study has been to give suggestions to guidelines for diagnosis and treatment of depression in MS in Denmark based on the international literature and recommendations. The method was a review of the relevant literature. The study recommends assessment of all MS patients for depression. Treatment of depression with serotonin reuptake inhibitors and/or cognitive behavioural therapy is recommended, depending on the severity of the illness. Caution is recommended in patients receiving beta interferon treatment.
authors.affiliation: Psykiatrisk Afdeling, Odense Universitetshospital, Odense, Denmark. e.stenager@hotmail.com
authors.forename: Elsebeth Nylev
authors.initials: EN
authors.lastname: Stenager
authors.forename: Kurt Bjerregaard
authors.initials: KB
authors.lastname: Stage
authors.forename: Egon
authors.initials: E
authors.lastname: Stenager
mesh_terms: D001714:Bipolar Disorder / Q000188:drug therapy / Q000209:etiology; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D016899:Interferon-beta; D017367:Selective Serotonin Reuptake Inhibitors